Association of day 16 residual leukemic bone marrow blasts with response to therapy and long-term outcome in cytogenetically defined subgroups
| End point . | Cytogenetics . | ||
|---|---|---|---|
| Favorable (n = 45) . | Intermediate (n = 217) . | Unfavorable (n = 59) . | |
| Complete remission | NS | P < .0001 | P = .0034 |
| Event-free survival | NS | P < .0001 | P = .0061 |
| Overall survival | NS | P = .0002 | P = .0418 |
| Median event-free survival, fewer than 10% versus 10% or more day 16 blasts | 25 mo vs NR, NS | 14 mo vs 5 mo, P = .00031 | 6 mo vs 2 mo, P = .00768 |
| Median overall survival, fewer than 10% versus 10% or more day 16 blasts | NR vs NR, NS | 26 mo vs 12 mo, P = .00263 | 11 mo vs 4 mo, P = .02095 |
| End point . | Cytogenetics . | ||
|---|---|---|---|
| Favorable (n = 45) . | Intermediate (n = 217) . | Unfavorable (n = 59) . | |
| Complete remission | NS | P < .0001 | P = .0034 |
| Event-free survival | NS | P < .0001 | P = .0061 |
| Overall survival | NS | P = .0002 | P = .0418 |
| Median event-free survival, fewer than 10% versus 10% or more day 16 blasts | 25 mo vs NR, NS | 14 mo vs 5 mo, P = .00031 | 6 mo vs 2 mo, P = .00768 |
| Median overall survival, fewer than 10% versus 10% or more day 16 blasts | NR vs NR, NS | 26 mo vs 12 mo, P = .00263 | 11 mo vs 4 mo, P = .02095 |
Univarite analyses for correlation of day 16 blasts as a continuous variable with the respective end points were performed within the respective groups with favorable, prognostically intermediate, and unfavorable cytogenetics. In addition, median event-free survival and median overall survival are shown for the respective cyogenetically defined risk groups as separated according to fewer than 10% versus 10% or more day 16 blasts. NS indicates not significant; NR, not reached.